References
- World Health Organization. Fact sheet on obesity. WHO; 2003. http://www.who.int/dietphysicalactivity/media/en/gsfs_obesity.pdf
- Finucane MM, et al. National, regional, and global trends in body-mass index since 1980 : systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011
- World Health Organization. Fact sheet: obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/
- World Health Organization. Obesity (body mass index > = 30) (age-standardized estimate). Data by country. http://apps.who.int/gho/data/node.main.A900A?lang=en
- Flegal KM, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999e2010. JAMA 2012;307:491-7
- Centers for Disease Control and Prevention (CDC). National center for health statistics. Prevalence of obesity among adults and youth: United States, 2015–2016. https://www.cdc.gov/nchs/products/databriefs/db288.htm
- National Audit Office. Tackling obesity in England: report by the Comptroller and Auditor General. London: Stationery Office: 2001. Br J Haematol 2013;162:25-39
- Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009;9:88
- McKinsey Global Institute. Overcoming obesity: an initial economic analysis. MGI; 2014. https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd = 2&cad=rja&uact = 8&ved = 0ahUKEwjErr74__fOAhUnIcAKHaNKBlUQFggmMAE&url=http%3A%2F%2Fwww.mckinsey.com%2F∼%2Fmedia%2FMcKinsey%2FBusiness%2520Functions%2FEconomic%2520Studies%2520TEMP%2FOur%2520Insights%2FHow%2520the%2520world%2520could%2520better%2520fight%2520obesity%2FMGI_Overcoming_obesity_Full_report.ashx&usg=AFQjCNF09cIsWK5RlbI19pO04CgrCkT4xA&bvm=bv.131783435,d.d2s
- Lehnert T, Sonntag D, Konnopka A, et al. Economic costs of overweight and obesity. Best practice & research. Clinical endocrinology & metabolism. 2013;27:105-15
- Specchia ML, Veneziano MA, Cadeddu C, et al. Economic impact of adult obesity on health systems: a systematic review. Eur J Public Health 2015;25:255-62
- Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg 2001;234:279-91
- Clegg A, Colquitt J, Sidhu M, et al. Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation. Int J Obes Relat Metab Disord 2003;27:1167-77
- Clegg A, Sidhu MK, Colquitt J, et al. Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-153
- Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obesity Rev 2011;12:50-61
- Begg S, Vos T, Barker B, et al. The burden of disease and injury in Australia 2003. Canberra: AIHW; 2007, Report No: PHE 82
- Public Health Group, Department of Human Services. Victorian Burden of Disease Study. Mortality and morbidity in 2001. Melbourne: Department of Human Services; 2005
- Carter R, Moodie M, Markwick A, et al. Assessing cost-effectiveness in obesity (ACE-obesity): an overview of the ACE approach, economic methods and cost results. BMC Public Health 2009;9:419
- Wadden TA, Foster GD, Letizia KA, et al. A multicenter evaluation of a proprietary weight reduction program for the treatment of marked obesity. Arch Intern Med 1992;152:961-6
- Bischoff S, et al. Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life—a prospective study. Int J Obes 2012;36:614-24
- Wadden TA, et al. Clinical correlates of short- and long-term weight loss. Am J Clin Nutr 1992:56:271S-274S
- Drawert S, Bedford K, Largent D. Change in glucose, blood pressure, and cholesterol with weight loss in medically obese patients. Obesity Res 1996;4:67S
- Cost effectiveness report of public health interventions to prevent obesity. Report prepared for the health research council of New Zealand. HTAnalysts; October 2010
- http://www.ispor.org/peguidelines/countrydet.asp?c=25&t=1
- Li Z, Tseng C-h, Li Q, et al. Clinical efficacy of a medically supervised outpatient high-protein, low-calorie diet program is equivalent in prediabetic, diabetic and normoglycemic obese patients. Nutr Diabetes 2014;4:e105
- Martin CK, O’Neil PM, Pawlow L. Changes in food cravings during low-calorie and very-low-calorie diets. Changes in food cravings during low-calorie and very-low-calorie diets. Obesity 2006;14:115-21
- McPherson K, Marsh T, Brown M, et al. Foresight tackling obesities: future choices. Modelling future tends in obesity and the impact on health. 2nd edn. 2007
- Picot J, Jones J, Colquitt JL, et al. Weight loss surgery for mild to moderate obesity: a systematic review and economic evaluation. Obes Surg 2012;22:1496-506
- Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009;13
- Wadden TA, Frey DL. A multicenter evaluation of a proprietary weight loss program for the treatment of marked obesity: a five-year follow-up. Int J Eat Disord 1997;22:203-12
- U.S. Food and Drug Administration. Saxenda. Liraglutide. Label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206321s003lbl.pdf
- European Medicines Agency. Saxenda. Liraglutide. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003780/human_med_001855.jsp&mid=WC0b01ac058001d124
- Toplak H, Woodward E, Yumuk V, et al. 2014 EASO position statement on the use of anti-obesity drugs. Obes Facts 2015;8:166-74
- Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol 2015;31:142-52
- Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342-62
- Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes 2013;37:1443-51
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized controlled trial of 3.0 mg liraglutide in weight management. N Engl J Med 2015;373:11-22
- ClinicalTrials.gov. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results – a long term evaluation (LEADER®). https://clinicaltrials.gov/ct2/show/NCT01179048
- Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013;166:823-30
- Daniels GH, Hegedu¨s L, Marso SP, et al. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial: preliminary observations. Diabetes Obes Metab 2015;17:477-86
- U.S. Food and Drug Administration. Contrave Label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf
- Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013;21:935-43
- Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 2011;19:110-20
- Torgerson JS, Sjostrom L. The Swedish Obese Subjects (SOS) study – rationale and results. Int J Obesity 2001;25(supp1):s2-s4
- www.pmlive.com/…/saxenda_debuts_in_us_with_USD1,000-a-month_price_tag_718145
- Bairdainl S, Samnaliev M. Cost-effectiveness of adolescent bariatric surgery. Cureus 2015;7:e248.
- Ward A, Alvarez P, Vo L, et al. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ 2014;17:176-83
- Willis M, Asseburg C, Neslusan C, et al. the economic impact of weight loss for patients with newly diagnosed type 2 diabetes mellitus (t2dm) in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 15th Annual International Meeting, May 15–19, 2010, Atlanta, GA
- Graci S, Izzo G, Savino S, et al. Weight cycling and cardiovascular risk factors in obesity. Int J Obes Relat Metab Disord 2004;28:65-71
- Montani JP, et al. Dieting and weight cycling as risk factors for cardiometabolic diseases: who is really at risk? Obesity Reviews 2015
- Beavers DP, et al. Cardiometabolic risk after weight loss and subsequent weight regain in overweight and obese postmenopausal women. J Gerontol A 2013;68:691-8
- Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff 2003;22:w3-219-26
- Finkelstein EA, DiBonaventura Md, Burgess SM, et al. The costs of obesity in the workplace. J Occup Environ Med 2010;52:971-6
- Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Affairs 2009;28:w822-31
- Wang Y, Beydoun MA, Liang L, et al. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity 2008;16:2323-30
- Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 2016;315:2284-91
- Dee A, Kearns K, O’Neill C, et al. The direct and indirect costs of both overweight and obesity: a systematic review. BMC Res Notes 2014;7:242